WHO Pharmaceuticals Newsletter 1999, No. 07&08
(1999; 18 pages)
Table of Contents
Close this folderRegulatory actions
View the documentAlbumin (human): review of safety: conclusions: UK
View the documentAstemizole: voluntary withdrawal: Janssen, USA
View the documentCisapride: revised labelling: QT syndrome and drug interactions: USA
View the documentFollitropin alfa: batch withdrawn: stability problems: EU
View the documentHetastarch (hydroxyethylstarch): fatal haemorrhages: France
View the documentMinocycline: immunoallergic and liver damage with long-term therapy: Germany
View the documentOral contraceptives containing gestodene or desogestrel: update: revised product information: UK
View the documentPemoline: revised labelling: liver function monitoring: Abbott, USA
View the documentPhenol: warning concerning topical solutions: New Zealand
View the documentProgestational drug products: requirements for patient labelling: proposed rule: USA
View the documentSubstandard medicines: distribution and prescription prohibited: Venezuela
View the documentSunscreen products: requirements: final rule: USA
View the documentTranylcypromine/trifluoperazine: licence not renewed: UK
View the documentTroglitazone: restricted indications: USA
View the documentTrovafloxacin and alatrofloxacin: suspended: Spain
Open this folder and view contentsDrug surveillance
Open this folder and view contentsNew developments
Open this folder and view contentsMedical devices
Open this folder and view contentsMedication errors
Open this folder and view contentsGeneral information
 

Follitropin alfa: batch withdrawn: stability problems: EU

European Union. The European Agency for the Evaluation of Medicinal Products has issued a Defective Product Recall concerning one batch of follitropin alfa (Gonal-F 150 IU: Serono Pharma) after quality control tests revealed concerns about stability.

The batch: No. B-3425: was found to be out of specification for Oxidized Forms at 3 months check points of the Stability Studies (19% vs 10% limit at shelf life). All other parameters were found to be within the limits.

The batch was distributed to Denmark, Finland, France, Germany, Italy, Sweden, UK and Latin America. It has been withdrawn by the company.

Reference: Defective Product Recall: EMEA, 5 May 1999.

to previous section to next section
 

Last updated: May 3, 2013